Parameters of oxidative stress and echocardiographic indexes in patients on dialysis therapy

Renal Failure

Volumn 32, Issue 3, 2010, Pages 328-334

  Kayabasi, Hasan ^a   Sit, Dede ^b   Atay, A Engin ^c   Yilmaz, Zulfukar ^d   Kadiroglu, Ali Kemal ^a   Yilmaz, M Emin ^a  

^a DICLE UNIVERSITY   (Turkey)

^b Fatih Government Hospital   (Turkey)

^c Diyarbakir Devlet Hastanesi   (Turkey)

^d Diyarbakir Children Hospital   (Turkey)

Author keywords

Dialysis; Echocardiographic indexes; Oxidative stress

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; FIBRINOGEN; GLUTATHIONE PEROXIDASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PARATHYROID HORMONE; PHOSPHORUS; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GROUPS BY AGE; HEART INDEX; HEART LEFT ATRIUM; HEART LEFT ATRIUM DIAMETER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART SIZE; HEART VENTRICLE SEPTUM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID PEROXIDATION; M MODE ECHOCARDIOGRAPHY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ECHOCARDIOGRAPHY; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS; SUPEROXIDE DISMUTASE;

EID: 77950563083     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003606299     Document Type: Article

References (32)

1. Locatelli F, Marcelli D, Conte F, et al. Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant. 2000;15(Suppl. 5):S69-S80.
2. Levey AS, Beto JA, Coronado BE, et al. Controling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998;32:853-906.
3. Sit D, Kadiroglu AK, Kayabasi H, et al. The evaluation incidence and risk factors of mortality among patients with end stage renal disease in Southeast Turkey. Ren Fail. 2008; 30(1):37-44.
4. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant. 2000;15:454-457.
5. Ronco C, La Greca G. Vitamin E bonded membrane, a further step in dialysis optizimation. Contrib Nephrol. 1999;127:1-31.
6. Sies H. Oxidants and antioxidants. Exp Physiol. 1997;82: 291-295.
7. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int. 1999;56:1078-1083.
8. Harma M, Harma M, Kocyigit A, Erel O. Increased DNA damage in patients with complete hydatiform mole. J Mutat Res. 2005;583:49-54.
9. Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorimetric determination of malondialdehyde. Clin Chem. 1991;37(7):1273-1275.
10. McCord JM, Fridovich I. Superoxide dismutase. An enzymatic function for erytrocuprein (hemocuprein). J Biol Chem. 1969;244:6049-6055.
11. Paglia DE, Valentina WN. Glutathione peroxi-dase. J Lab Clin Med. 1967;70:158.
12. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003; 16(2):101-105. (Pubitemid 37361072)
13. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-2217.
14. Tsirpanlis G. Cellular senescence, cardiovascular risk, and CKD: A review of established and hypothetical interconnections. Am J Kidney Dis. 2008;51(1):131-144.
15. Matteucci E, Cupisti A, Caprioli R, et al. Erythrocyte transmembrane electron transfer in hemodialysis patients. Nutr Metab Cardiovasc Dis. 2007;17(4):288-293.
16. Avissar N, Ornt BA, Yagil Y, Horowitz S. Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol. 1994;266:367-375.
17. Çeliker H, Elkiran B, Ilhan N, Günal AI, Dogukan A. The effects of hemodialysis and peritoneal dialysis on oxidative stres parameters. Official J Turk Soc Nephrol. 2001;10(2):88-92.
18. Köse K, Dogan P, Gündüz S, Düsünsel R, Utas C. Oxidative stress in hemodialysis patients and long term effects of dialyzer reuse practice. Clin Biochem. 1997;30:601-606.
19. Wu CC, Chen JS, Wu WM, et al. Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 2005;20(6):1134-1139.
20. Ilgen C, Bulucu F, Yamanel L, et al. The effect of different dialyzer membranes on the oxidative burst status of polymorphonuclear leukocytes in hemodialysis patients. Official J Turk Soc Nephrol. 2007;16(2):63-67.
21. Johnson DW, Armstrong K, Campbell SB, et al. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007;12(4):391-398.
22. Cristol JP, Bose JY, Badiou S, et al. Erythropoietin and oxidative stress in hemodialysis. Benefical effects of vitamin E supplementation. Nephrol Dial Transplant. 1997;12:2312-2317.
23. Rysz J, Stolarek RA, Pedzik A, et al. Increased exhaled H2O2 and impaired lung function in patients undergoing bioincompatible hemodialysis. Int J Artif Organs. 2007;30(10): 879-888.
24. Biasioli S, Schiavon R, Petrosino L, et al. Free radicals and oxidative stress challenge dialysis patients: Effects of two different membranes. ASAIO J. 1997;43(5):M766-M772.
25. Al-Hashimi AF, Mohammed FH, Al-Khazragi AS. Oxidative stress in chronic renal failure patients treated by peritoneal dialysis. Saudi Med J. 2004;25(9):1186-1192.
26. Yano S. Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease. Clin Calcium. 2007;17(12):1870-1878.
27. Pawlak K, Pawlak D, Mysliwiec M. Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure. Pol Arch Med Wewn. 2005;113(1):21-26.
28. Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: Sources and consequences. Clin Nephrol. 2007;68(1):1-9.
29. Scott B, Deman A, Peeters P, et al. Cardiac troponin T and malondialdehyde modified plasma lipids in hemodialysis patients. Nephrol Dial Transplant. 2003;18(4):737-742.
30. Ece A, Gürkan F, Kervancioglu M, et al. Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol. 2006;21(4): 545-552.
31. Gugliucci A, Mehlhaff K, Kinugasa E, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: Correlation with low molecular AGE adduct clearance. Clin Chim Acta. 2007;377(1-2):213-220.
32. Liao Y Cooper RS, McGee DL, Mensah G, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597.